Osteopontin as a marker of weight loss in lung cancer

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 71, Issue 8, 2011, Pages 690-694

  Karadag, Fisun ^a   Gulen, Sule T ^a   Karul, Aslihan B ^a   Kilicarslan, Naciye ^a   Ceylan, Emel ^a   Kuman, Nilgun K ^a   Cildag, Orhan ^a  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

Author keywords

C reactive protein; lung cancer; osteopontin; systemic inflammation; TNF

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; OSTEOPONTIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TURBIDIMETRY; WEIGHT REDUCTION;

AGED; BODY MASS INDEX; C-REACTIVE PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFLAMMATION; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OSTEOPONTIN; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA; TURKEY; WEIGHT LOSS;

EID: 81255128868     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2011.621549     Document Type: Article

References (24)

1. Scott HR, McMillan DC, Brown DJF, Forrest LM, McArdle CS, Milroy R. A prospective study of the impact of weight loss and the systemic infl ammatory response on quality of life in patients with inoperable non-small cell lung cancer. Lung Cancer 2003;40:295-9.
2. Martin F, Santolaria F, Batista N, Milena A, Reimers EG, Brito MJ, Oramas J. Cytokine concentrations (IL6 and IFNγ?) acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999;11:80-6.
3. Jamieson NB, Brown JFD, Wallace AM, McMillan DC. Adiponectin and the systemic infl ammatory response in weight-losing patients with non-small cell lung cancer. Cytokine 2004;27:90-2.
4. McKeown DJ, Brown DJF, Kelly A, Wallace AM, McMillan DC. The relationship between circulating concentrations of C-reactive protein, infl ammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer 2004;91:1993 - 5.
5. Scott HR, McMillan DC, Crilly A, McArdle CS, Milroy R. The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br J Cancer 1996;73:1560-2.
6. O' R egan A. The role of osteopontin in lung disease. Cytokine Growth Factor Rev 2003;14:479-88.
7. Zhang J, Takahashi K, Takahashi F, Shimizu K, Ohshita F, Kameda Y, et al. Differential osteopontin expression in lung cancer. Cancer Lett 2001;171:215-22.
8. Chambers AF, Wilson SM, Kerkvliet N, O' M alley FP, H arris JF, Casson AG. Osteopontin expression in lung cancer. Lung Cancer 1996;15:311-23.
9. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 2007;57:373-80.
10. Zhi Hu, Lin D, Yuan J, Xiao T, Zhang H, Sun W, et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 2005;11:4646-52.
11. Donati V, Boldrini L, Dell' O modarme M, Prati MC, Faviana P, Camacci T, et al. Osteopontin expression and prognostic signifi cance in non-small cell lung cancer. Clin Cancer Res 2005;11:6459-65.
12. Lund SA, Giachelli CM. The role of osteopontin in infl amatory processes. J Cell Commun Signal 2009;3:311-22.
13. Detterbeck FC, Boffa DJ, Tanoue LT. The New Lung Cancer Staging System. Chest 2009;136:260-71.
14. Mantovani G, Maccio A, Madeddu C, Mura L, Massa E, Mudu MC, et al. Serum values of proinfl ammatory cytokines are inversely correlated with serum leptin concentrations in patients with advanced stage cancer at different sites. J Mol Med 2001;79:406-14.
15. Pisani RJ. Bronchogenic carcinoma: immunologic aspects. Mayo Clin Proc 1993;68:386-92.
16. Matanic D, Beg-Zec Z, Stojanovic D, Matakoric-Mileusnic N, Flego V, Milevoj-Ribic F. Cytokines in patients with lung cancer. Scand J Immunol 2002;57:173-8.
17. Inui A. Cancer Anorexia-Cachexia Syndrome: Current issues in research and management. CA Cancer J Clin 2002;52: 72-91.
18. Simons JP, Schols AM, Buurman WA, Wouters EF. Weight loss and low body cell mass in males with lung cancer: Relationship with systemic infl ammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci 1999;97:215-23.
19. Sherry B, Cerami A. Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of infl amatory responses. J Cell Biol 1988;107:1269-77.
20. Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines, and disease. Annu Rev Cell Biol 1993;9:317-43.
21. Weber GF, Zawaideh S, Hikita S, Kumar VA, Cantor H, Ashkar S. Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. J Leukoc Biol 2002;72:752-61.
22. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, et al. Eta-1 (osteopontin): An early component of type 1 (cell-mediated) immunity. Science 2000; 287:860-4.
23. Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, et al. The infl uence of the proinfl amatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001;294:1731-5.
24. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001;7:4060-6.